In the fourth quarter, Revolve’s stock rose as its revenue met expectations with a 4.4% year-over-year increase. In fiscal second quarter 2026, Haemonetics delivered strong performance, raising ...

In 2025, my biotech-focused portfolio delivered a 34.3% average return, outperforming the S&P 500 by 20.6%. I prioritize small- and mid-cap biotechs with FDA-approved drugs entering commercialization, ...

Lockheed Martin's one-year performance has severely lagged the broader market. Even a three-year investment in Lockheed has lost money. If you haven't been paying attention, Lockheed's recent stock ...

JPMorgan Chase & Co.’s decision to let managers use artificial intelligence to help write performance reviews stands to bring relief to one of bosses’ most dreaded annual tasks. It also raises ...